EU Paediatric Regulation “not tackling off-label use of existing drugs”
This article was originally published in SRA
Executive Summary
The EU Paediatric Regulation has not helped reduce the off-label use of medicines in children, the European Medicines Agency's Network of Paediatric Research (Enpr-EMA) has stated in a report outlining its experience with the legislation1.
You may also be interested in...
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.
EMA To Get The Ball Rolling On Making CTIS Global
The European Medicines Agency wants to further improve the visibility of data in the Clinical Trials Information System by establishing it as a World Health Organization primary registry.
EMA Presses On With Keenly-Awaited Guidance On How To Use Patient Experience Data
While the International Council of Harmonisation is developing a harmonized approach to patient-focused drug development, the European Medicines Agency has heeded calls for “prompt guidance” to support the systematic inclusion of patient experience data in regulatory submissions.